Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Neural Regulation01:37

Neural Regulation

43.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.6K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Role of Cerebellum and Prefrontal Cortex in Memory01:14

Role of Cerebellum and Prefrontal Cortex in Memory

1.3K
The cerebellum, while traditionally associated with motor control, also plays a crucial role in memory, particularly in procedural memory, which involves learning motor tasks that become automatic through repetition. For example, studies have shown that when the cerebellum is damaged, individuals or animals lose the ability to learn conditioned motor responses, such as the conditioned eye-blink response in classical conditioning experiments with rabbits. This study demonstrates the...
1.3K
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

748
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
748

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Compositional recombination is facilitated by a distributed cortico-cerebellar network.

Cell reports·2026
Same author

Mirabegron and Intradetrusor Onabotulinumtoxina for Overactive Bladder in Parkinson's Disease: A Systematic Review and Meta-Analysis.

Neurourology and urodynamics·2026
Same author

Reduced serum interleukin-2 associates with higher motor severity and along with CD4 T cell alterations may be an early event in isolated REM Sleep Behaviour Disorder.

Brain, behavior, & immunity - health·2026
Same author

Feasibility of Internet-Based Mind-Body Training for Adults With Subjective Cognitive Decline: Protocol for a Randomized Controlled Trial.

JMIR research protocols·2026
Same author

What is new in Freezing of Gait?

Journal of neurology·2026
Same author

Elevation of Stearoyl-Coenzyme A Desaturase and Monounsaturated Fatty Acids in Parkinson's Disease Serum.

Movement disorders : official journal of the Movement Disorder Society·2026

Related Experiment Video

Updated: Feb 24, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.4K

Cognition in Parkinson's Disease.

Claire O'Callaghan1, Simon J G Lewis2

  • 1University of Cambridge, Cambridge, United Kingdom; Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia.

International Review of Neurobiology
|August 14, 2017
PubMed
Summary

Cognitive decline is a common Parkinson's disease symptom, presenting as executive dysfunction or dementia. Research explores its neural basis, neurotransmitter changes, and genetic links, with developing therapeutic strategies.

Keywords:
AcetylcholineDopamineGenetic impact on cognitionNeurotransmitters and cognitionNoradrenalineParkinson's disease cognitionParkinson's disease dementiaParkinson's disease mild cognitive impairmentSerotonin

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.4K
Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

16.4K

Related Experiment Videos

Last Updated: Feb 24, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.4K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.4K
Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

16.4K

Area of Science:

  • Neuroscience
  • Neurology
  • Gerontology

Background:

  • Cognitive decline is a prevalent nonmotor symptom in Parkinson's disease (PD).
  • Deficits range from executive dysfunction in early stages to dementia in later progression.
  • Understanding the neural and genetic underpinnings is crucial for effective management.

Purpose of the Study:

  • To review the current understanding of cognitive decline in Parkinson's disease.
  • To explore the neural correlates, neurotransmitter involvement, and genetic factors contributing to cognitive impairment in PD.
  • To summarize the current state of therapeutic interventions for cognitive decline in PD.

Main Methods:

  • Review of multimodal neuroimaging techniques (structural, functional, metabolic).
  • Analysis of neurotransmitter system involvement (dopamine, norepinephrine, serotonin, acetylcholine).
  • Examination of genetic associations (COMT, MAPT, APOE, GBA polymorphisms).

Main Results:

  • Dopaminergic dysfunction underlies early executive deficits; broader neurodegeneration contributes to dementia.
  • Non-dopaminergic systems (noradrenergic, serotonergic, cholinergic) significantly impact cognition.
  • Specific genetic variations (e.g., APOE, GBA) are linked to cognitive decline in PD patients.

Conclusions:

  • Cognitive decline in Parkinson's disease is multifactorial, involving complex neural and genetic elements.
  • Targeting non-dopaminergic systems and considering genetic predispositions may offer new therapeutic avenues.
  • Further research is needed to develop robust pharmacological and non-pharmacological treatments for cognitive impairment in PD.